The cardiotonic effect of pimobendan was studied in 6 dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital. Pimobendan in doses of 1-10mg improved cardiac function in a dose-dependent manner and at 10mg improved it beyond the control. These doses of pimobendan, however, produced neither a significant increase in heart rate nor arrhythmias. The results indicate that the drug may be of use in the treatment of heart failure. (Jpn Heart J 34: 213-219, 1993.) Key Words: Heart failure Positive inotropic drug Ca-sensitizer PDE inhibitor IMOBENDAN (UD-CG 115 BS) is one of the newer positive inotropic agents. The inotropic properties of this benzimidazole-pyridazinone derivative have been shown in isolated guinea pig papillary muscles.1),2) Two mechanisms contribute to this inotropic activity: An inhibition of cAMP-phosphodiesterase (type III),3) and an increase in the calcium sensitivity of cardiac myofibrils.4) Consequently, pimobendan exerts a vasodilatory as well as a positive inotropic effect. Many newer positive inotropic drugs have been developed, such as amrinone, milrinone, sulmazole, enoximone, piroximone, vesnarinone, and MCI-154, hopefully as substitutes for digitalis. Previously, we investigated the effects of such drugs on experimental heart failure produced by pentobarbital.7)-11) Thus, it was of interest to see whether pimobendan is as efficacious at improving the experimental failing heart as other newer positive inotropic drugs.
were induced by pimobendan at any of the doses used.
DISCUSSION
From the results presented here, it is evident that pimobendan-is effective in improving cardiac performance depressed by pentobarbital. Almost -complete restoration of the cardiac performance of the failing heart, in which cardiac output had been reduced to about 50% of the control value, was attained with 3mg pimobendan. At this dose, heart rate almost recovered to the control value, whereas LV dP/dt max increased by about 7%. At 10mg pimobendan, LV dP/ dt max increased by 66% of the control value, whereas heart rate increased by only 8 beats/min over the control value. Thus, the force-rate separation of pimobendan was marked. These results were deducible from the cardiovascular profile of pimobendan delineated in the isolated, blood-perfused dog heart preparations.13) In the blood-perfused dog heart preparations, pimobendan showed a sizeable force-rate separation; pimobendan increased sinus-rate by about 19% at the dose that produced a 50% increase in the force of contraction of the ventricular myocardium. In the present heart-failure conditions, pimobendan showed a force-rate separation to a similar extent. The definite force-rate separation is considered to be essential for a positive inotropic drug that is used for heart failure. Additionally, pimobendan produced no arrhythmias. Pimobendan has been shown to be more potent than amrinone, a prototype positive inotropic drug; when compared at doses that restored the depressed cardiac function curve to the control in the dog heart-lung preparation, the cardiotonic potency of pimobendan appears to be more than 3 times that of amrinone.8) Furthermore, amrinone failed to restore the depressed cardiac function curve to the control even with high doses,8) whereas pimobendan improved the depressed cardiac function curve over the control with 10mg.
In similar previous experiments, sulmazole9) and MCI-154,11) cardiotonic agents having a Ca-sensitizing action, improved the depressed cardiac function curve compared to the control like pimobendan did, whereas the non-selective PDE inhibitor trapidil14) failed to restore the depressed cardiac function curve, even at the high doses at which amrinone failed to do so.8) Thus, in the failing heart, the Ca-sensitizing action of the drugs appears to contribute to their cardiotonic property to improve the depressed cardiac function curve compared to the control, although the cardiovascular profiles of pimobendan and the other PDE inhibitors without such action are similar in the normal heart. However, this is not actually so. The specific PDE III inhibitors enoximone or piroximone improved the depressed cardiac function curve compared to the control as did pimobendan, sulmazole9) and MCI-154.11) The specific PDE III inhibitor Jpn. Heart J. March, 1993 amrinone, however, did not exert such an effect.8) Thus, it is impossible to explain the advantage of pimobendan on the basis of its characteristics as a Casensitizer.
Even at the highest doses, pimobendan did not increase heart rate and did not accelerate AV conduction. Furthermore, pimobendan, unlike digitalis, produced no arrhythmias. These results indicate that pimobendan is a potentially useful drug for the treatment of congestive heart failure.
ACKNOWLEDGMENTS
We are grateful to Prof. Dr. Mittmann of Dr. Karl Thomae GmbH, Bieberach an der Riss, Germany for kindly supplying the pimobendan.
